Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | APP | P05067 | 6/20 | 0.60 |
| ▸ | GABRP | O00591 | 1/20 | 0.53 |
| ▸ | GABRD | O14764 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.53 |
| ▸ | GABRE | P78334 | 1/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832948 | 0.88 | HTR2C (0.62) | HTR2CADRB2APPGABRPGABRD | |
| SCHEMBL12367411 | 0.87 | IDO1 (0.54) | HTR2CADRB2APPIDO1SLC6A4 | |
| Hydrochloric Acid SCHEMBL30375480 | 0.86 | HTR2C (0.63) | HTR2CADRB2APPGABRPGABRD | |
| SCHEMBL12367426 | 0.84 | IDO1 (0.51) | HTR2CADRB2APPGABRPGABRD | |
| SCHEMBL4676876 | 0.83 | IDO1 (0.50) | HTR2CADRB2APPGABRPGABRD | |
| SCHEMBL23010845 | 0.82 | APP (0.64) | APPIDO1SLC6A4DRD2 | |
| SCHEMBL8298760 | 0.82 | HTR2C (0.59) | HTR2CADRB2APPGABRPGABRD | |
| SCHEMBL21089078 | 0.81 | HTR2C (0.62) | HTR2CADRB2APPSLC6A4DRD2 | |
| SCHEMBL4675208 | 0.81 | HTR2C (0.62) | HTR2CADRB2APPIDO1SLC6A4 | |
| SCHEMBL30275187 | 0.81 | HTR2A (0.64) | HTR2CADRB2APPIDO1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| WO-2021030620-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| CN-107922347-A | New imide derivative and its purposes as medicine | 田边三菱制药株式会社 | 2018-04-17 | — | — | CN | disclosed |
| WO-2015082499-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2015-06-11 | — | — | WO | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-5741789-A | HETERO-OXY ALKANAMINES | ELI LILLY AND COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| CN-1178530-A | Compounds having an effect on 5-hydroxytryptamine related systems | LILLY CO ELI (US) | 1998-04-08 | — | — | CN | disclosed |
| WO-1997047302-A1 | INHIBITION OF SEROTONIN REUPTAKE | ELI LILLY AND COMPANY (US) | 1997-12-18 | — | — | WO | disclosed |
| EP-0812826-A1 | 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5683998-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS, ANTIPAF AGENTS | TORAY INDUSTRIES, INC. (JP) | 1997-11-04 | — | — | US | disclosed |
| US-5627196-A | ANTIDEPRESSANTS AND ANTISEROTONIN AGENTS | ELI LILLY AND COMPANY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5614523-A | INDOLYLOXY COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| US-5576321-A | ALKOXY-SUBSTITUTED INDOLES | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0722941-A2 | Compounds having effects on serotonin-related systems | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0536419-A1 | TRICYCLIC TRIAZOLE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | HTR2C 3534/4885ADRB2 4004/4885APP 4540/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | HTR2C 3675/4885ADRB2 4087/4885APP 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.